

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



EPS Creative Health Technology Group Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 3860)

CHANGE OF EXECUTIVE DIRECTOR, CHAIRMAN AND CHIEF EXECUTIVE OFFICER

The Board hereby announces the following appointment and resignation with effect from 8 November 2024:

- (1) Mr. Shimada has tendered his resignation as an executive Director, the Chairman and the Chief Executive Officer; and
- (2) Mr. Washikita has been appointed as an executive Director, the Chairman and the Chief Executive Officer.

RESIGNATION OF EXECUTIVE DIRECTOR, CHAIRMAN AND CHIEF EXECUTIVE OFFICER

The board (the “**Board**”) of directors (the “**Directors**”) of EPS Creative Health Technology Group Limited (the “**Company**”) announces that Mr. Shimada Tatsuji (“**Mr. Shimada**”) has tendered his resignation as an executive Director, the chairman of the Board (the “**Chairman**”) and the chief executive officer of the Company (the “**Chief Executive Officer**”) with effect from 8 November 2024 in order to focus on his other business engagements.

Mr. Shimada has confirmed that he has no disagreement with the Board and that he is not aware of any other matters relating to his resignation that need to be brought to the attention of the shareholders of the Company (the “**Shareholders**”) and The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

The Board would like to take this opportunity to express its sincere gratitude to Mr. Shimada for his contribution to the Company during his tenure of office.

APPOINTMENT OF EXECUTIVE DIRECTOR, CHAIRMAN AND CHIEF EXECUTIVE OFFICER

The Board is pleased to announce that Mr. Washikita Kenichiro (“**Mr. Washikita**”) has been appointed as an executive Director, the Chairman and the Chief Executive Officer with effect from 8 November 2024. The biographical details of Mr. Washikita are set out as follows:

Mr. Washikita, aged 60, is the Corporate Officer of EPS Holdings, Inc. (“**EPS Japan**”), which is a controlling shareholder (as defined under the Rules (the “**Listing Rules**”) Governing the Listing of Securities on the Stock Exchange) of the Company. Mr. Washikita joined EPS Japan in April 2024 and has over 37 years of experience in diversified business areas including apparel and medical healthcare. Prior to joining EPS Japan, Mr. Washikita worked in Mitsui & Co., Ltd., a Japanese company which is part of the Mitsui Group, an international group offering diversified services worldwide, from 1987 to March 2024 in which he had been the General Manager of various business units and the Chairman and Managing Director of Mitsui & Co. (Hong Kong) Ltd. He also served in various positions within the Hong Kong Japanese Chamber of Commerce and Industry, being the President from April to June 2018, the Vice President from July 2018 to June 2019 and from July 2022 to March 2024, and the first Health Care & Medical Committee Head from September 2021 to March 2024. Mr. Washikita is a colleague of Mr. Miyano Tsumoru and Mr. Maezaki Masahiro and Mr. Chiu Chun Tak, the existing executive Directors, and Mr. Kusaba Takuya, an existing non-executive Director, in EPS Japan.

Mr. Washikita graduated from Waseda University in Shinjuku, Tokyo, Japan, majoring in B.A. Political Science and Economic in 1987. He also received an MBA degree from Aoyama Gakuin University in Shibuya, Tokyo, Japan in 2007.

Pursuant to the letter of appointment entered into between the Company and Mr. Washikita, he has been appointed for a term of two years commencing from 8 November 2024 and is subject to the provision of retirement by rotation and re-election at the annual general meeting of the Company at least once every three years in accordance with the articles of association of the Company. According to the terms of the letter of appointment, Mr. Washikita is entitled to a monthly salary of JPY353,000 on a 13-month basis and a year-end discretionary bonus, which has been recommended by the remuneration committee of the Board and approved by the Board with reference to his qualifications, experience and responsibilities with the Company.

As at the date of this announcement, save as disclosed above, Mr. Washikita (i) does not hold any other position with the Company or any of its subsidiaries; (ii) has not held any other directorship in, or direct or indirect interest in 10% or more of the issued share capital of, any other public companies the securities of which are listed on any security market in Hong Kong or overseas in the three years prior to the date of this announcement; (iii) does not have any other relationship with any directors, senior management or substantial or controlling shareholders (as defined under the Listing Rules) of the Company; and (iv) does not have any interest in the shares or underlying shares of the Company (within the meaning of Part XV of the Securities and Futures Ordinance, Chapter 571 of the Laws of Hong Kong).

Save as disclosed above, there is no information in relation to the appointment of Mr. Washikita that is required to be disclosed pursuant to any of the requirements under paragraphs (h) to (v) of Rule 13.51(2) of the Listing Rules, and there is no other matter that needs to be brought to the attention of the Shareholders.

The Board would like to take this opportunity to express its warmest welcome to Mr. Washikita for joining the Board.

By order of the Board
EPS Creative Health Technology Group Limited
Miyano Tsumoru
Executive Director

Hong Kong, 8 November 2024

As at the date of this announcement, the executive Directors are Mr. Washikita Kenichiro, Mr. Miyano Tsumoru, Mr. Maezaki Masahiro, Mr. Miyazato Hiroki and Mr. Chiu Chun Tak; the non-executive Directors are Mr. Kusaba Takuya and Mr. Yan Ping; and the independent non-executive Directors are Mr. Chan Cheuk Ho, Mr. Choi Koon Ming, Mr. Saito Hironobu and Mr. Taniguchi Yasuhiko.